Skip to main content icon/video/no-internet

Cardiovascular disease (CVD) ranks as the leading cause of morbidity and mortality among developed countries and is rapidly emerging as the predominant cause of death in many developing countries. There are numerous differences in incidence across ethnic groups and geographic regions within countries. Coronary heart disease (CHD) is the predominant manifestation of CVD and responsible for the majority of cases of CVD in developed countries. Numerous longitudinal epidemiological studies conducted in the past 60 years have provided valuable insight into the natural history and risk factors associated with the development of and prognosis associated with CVD. Randomized clinical trials have demonstrated the value of treatment of several key risk factors, most notably hypertension and hypercholesterolemia, for both the primary and the secondary prevention of CVD. This entry reviews the descriptive epidemiology of CVD, its associated risk factors, assessment of CVD risk, and the evidence behind the control of CVD risk factors for the prevention of CVD.

Definitions, Incidence, and Distribution

CVD comprises many conditions, including CHD, heart failure, rheumatic fever or rheumatic heart disease, stroke, and congenital heart disease. Of these, 7 in 10 deaths from CVD are due to CHD (53%) and stroke (17%) (Figure 1). CHD, the most common CVD condition, increases in prevalence directly with age in both men and women (Figure 2).

Myocardial infarction, angina pectoris (especially if requiring hospitalization), and sudden coronary death are the major clinical manifestations of CHD. CHD initially presents as sudden coronary death in approximately one third of the cases. Other forms of documented CHD include procedures done as a result of documented significant atherosclerosis, such as coronary artery bypass grafting (CABG) or percutaneous coronary interventions (PCI), including angioplasty and stenting. Persons with documented significant disease from a coronary angiogram, echocardiogram, nuclear myocardial perfusion, magnetic resonance imaging, or computed tomography angiographic or coronary calcium scan can also confirm the presence and extent of coronary artery disease; however, because the definitions used to define significant disease vary and/or such results do not typically result in hospitalization, these cases are not normally counted as incident or prevalent CHD, nor are they considered ‘hard’ (usually death or hospitalized diagnosed conditions) cardiovascular endpoints for the purposes of clinical trials. Nonfatal or fatal myocardial infarction and sudden coronary death are most typically included as ‘hard’ CHD endpoints.

Figure 1 Percentage Breakdown of Deaths From Cardiovascular Disease

None

Mortality rates from CVD and CHD vary widely across different countries. From the most recent data available, among men, CVD death rates per 100,000 range from 170 in Japan to 1,167 in the Russian Federation, with the United States at 307. Corresponding CHD death rates were 53, 639, and 187, respectively. Among women, these rates were lowest in France but highest in the Russian Federation, with intermediate rates in the United States. These rates were 69, 540, and 158 for CVD, respectively, and 18, 230, and 77 for CHD, respectively. Next to the Russian Federation, Romania, Bulgaria, and Hungary had the next highest rates both for CVD and CHD. Spain, Australia, Switzerland, and France (or Japan) were the other countries with the lowest rates.

...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles

Sage Recommends

We found other relevant content for you on other Sage platforms.

Loading